LGLiana Gercheva

Liana Gercheva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liana Gercheva has a total of 204 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials

    by Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, et al.

    Introduction: Ropeginterferon alfa-2b (BESREMi®), a novel pegylated interferon with an extended half-life, was approved in Europe for treatment of patients with PV based on results from the phase 3 PROUD-PV and CONTINUATION-PV trials. Ropeginterferon alfa-2b treatment is recommended in hydroxyurea (HU) naïve patients as well as in those who have previously received HU. Therefore, treatment response was analyzed by prior HU treatment status, and the influence of baseline JAK2V617F allele burden and additional mutations - which may increase over time during non-disease modifying treatment - was explored. Methods: In PROUD-PV, patients aged ≥18 years, diagnosed with PV according to WHO 2008 criteria, and either cytoreduction-naïve or HU-pre-treated (for 50%), and in patients with available data (N=159), by the presence of non-driver mutations (TruSight™ Myeloid Panel, Illumina) or chromosomal aberrations (Affymetrix SNP6.0 array) at baseline. Results: After 5 years of treatment with ropeginterferon alfa-2b, high rates of CHR were sustained in both HU-naïve and HU pre-treated patients (53.1% and 61.3%, respectively), whereas in the control arm, the CHR rate was lower among HU pre-treated patients (36.0% compared to 48.0% for HU-naïve patients). Molecular response rates at 5 years in HU naïve and pre-treated patients were 71.4% and 64.5% respectively in the ropeginterferon alfa-2b arm and 26.0% versus 12.5% respectively in the control arm. Rates of adverse events (AEs), treatment-related AEs, serious AEs, and AEs leading to discontinuation were similar between the subgroups regardless of HU pre-treatment. Similar CHR rates were observed at 5 years irrespective of baseline JAK2V617F allele burden category (ropeginterferon alfa-2b arm: 57.1% versus 53.1% for allele burden ≤50% or >50%, respectively; control: 46.9% versus 38.5%, respectively). The molecular response rate in the ropeginterferon alfa-2b arm was higher among patients with baseline allele burden >50% (84.4% versus 61.3% for allele burden ≤50%); in the control arm there was no difference in molecular response rates between the allele burden subgroups (23.1% versus 20.8%, respectively). Of interest, the presence of non-driver mutations or chromosomal aberrations at baseline had no apparent influence on molecular response rates to ropeginterferon alfa-2b (64.5% compared with 70.7% in patients without these genetic abnormalities). Conclusion: High hematologic and molecular response rates in both HU-pretreated and HU-naïve patients and in those with more advanced JAK2V617F burden suggest that ropeginterferon alfa-2b is also a suitable treatment option in patients switching from HU. Disclosures: Gisslinger: AOP Orphan Pharmaceuticals GmbH: Other: Personal fees, Research Funding; Novartis: Other: Personal fees, Research Funding; PharmaEssentia: Other: Personal fees; MyeloPro Diagnostics and Research: Other: Personal fees; Janssen-Cilag: Other: Personal fees; Roche: Other: Personal fees; Celgene: Other: Personal fees. Klade: AOP Orphan Pharmaceuticals GmbH: Current Employment. Pylypenko: Communal nonprofit enterprise "Cherkasy regional oncology dispensary of Cherkasy oblast council: Current Employment. Mayer: AOP Orphan Pharmaceuticals GmbH: Research Funding. Krejcy: AOP Orphan Pharmaceuticals GmbH: Current Employment. Empson: AOP Orphan Pharmaceuticals GmbH: Current Employment. Hasselbalch: Novartis, AOP Orphan: Consultancy, Other: Advisory Board. Kralovics: AOP Orphan Pharmaceuticals GmbH: Other: Personal fees; PharmaEssentia: Other: Personal fees; Qiagen: Other: Personal fees; Novartis: Other: Personal fees; MyeloPro Diagnostics and Research: Current holder of individual stocks in a privately-held company. Kiladjian: Novartis: Membership on an entity's Board of Directors or advisory committees; AOP Orphan: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Incyte Corporation: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Other: Personal fees; Taiho Oncology, Inc.: Research Funding.


  • Detection of Еpstein‑Barr Virus DNA in Patients with Hodgkin Lymphoma

    by Tsvetelina Kostadinova Popova, Liliya Ivanova, Ivaylo Hristov, Zhivka Stoykova, Tatina Todorova, Merlin Erol Efraim, Liana Gercheva

  • Open Access

    Detection of EBV DNA in Non-Hodgkin Lymphoma Patients in Bulgaria

    by Tsvetelina Kostadinova, Liliya Ivanova Ivanova, Tatina Todorova Todorova, Zhivka Stoykova, Dobromir Staykov, Merlin Efraim, Liana Gercheva

    Epstein–Barr virus is the first human oncogenic virus associated with a broad range of different malignant diseases but its role in non-Hodgkin lymphomas (NHL) development still needs to be fully understood. High expression levels of EBV major genes are found in NHL tumor cells and free viral DNA circulates in the plasma of such individuals. In the current study we detected EBV DNA levels in plasma samples from NHL patients in order to validate its significance as a laboratory marker for disease monitoring. We investigated a cohort of 52 patients diagnosed with NHL in The University Hospital “St. Marina” Varna, Bulgaria. Viral DNA was extracted from single plasma samples using Kit Ribo Virus (Sacace Biotechnologies S.r.l., Como, Italy) and amplified with EBV Real-TM Quant (Sacace Biotechnologies S.r.l., Como, Italy). Plasma samples of the same patients were tested for presence of EBV VCA IgM/IgG antibodies with indirect ELISA tests (Euroimmun, Luebeck, Germany). We found 15.4% (95% CI 6.9–28.1%, n = 8) of the samples from NHL patients to be positive in quantitative PCR (range 674–221,333 copies/ml). The diffuse large B cell lymphomas and peripheral T cell lymphomas were most often associated (although not statistically significant, p = 0.167) with detectable plasma EBV DNA levels. To our knowledge, this is the first study about the role of EBV in NHL development in Bulgaria. The results we have obtained should stimulate new, larger investigations to apply the quantitative PCR technique in the routine laboratory EBV diagnosis.


  • Open Access

    INVESTIGATION OF IMMUNOSUPPRESSED PATIENTS FOR THE PRESENCE OF EBV DNA IN REAL TIME PCR

    by Tsvetelina Kostadinova, Liliya Ivanova, Zhivka Stoykova, Tatina T. Todorova, Liana Gercheva, Dobromir Staykov, Bulgaria Regional Center Of Transfusion Hematology - Varna, Denitsa Tsaneva

  • Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial

    by Richard Greil, Petra Obrtlíková, Lukáš Smolej, Tomáš Kozák, Michael Steurer, Johannes Andel, Sonja Burgstaller, Eva Mikušková, Liana Gercheva, Thomas Nösslinger, et al.


  • Open Access

    CHRONIC MYELOMONOCYTIC LEUKEMIA - REVIEW AND CLINICAL EXPERIENCE OF THE HEMATOLOGY DEPARTMENT UMHAT "ST. MARINA" - VARNA

    by Ilina Micheva, Trifon Chervenkov, Canka Ruseva, Liana Gercheva

    Chronic myelomonocytic leukemia (CMML) is a rare de novo myeloid neoplasm that exhibits dysplastic and proliferative features at presentation. The diagnosis is problematic with several specific controversial issues. \ud Aim: To analyze the cases with CMML diagnosed in the Hematology clinic, UMHAT “St. Marina”, Varna with assessment of risk, prognosis and survival.\ud Materials and methods: The results from cytology, flow cytometry, histology, and genetics are re-estimated. For the risk stratification the CPSS was used. The statistical analysis is performed using SPSS 19.\ud Results: Fifteen patients with CMML, 12 men and 3 women, with median age of 69,8 years were included in the study. According to the leukocyte count 12 were myeloproliferative (CMML/MP) and 3 myelodysplastic CMML (CMML/MD). The flow cytometry of peripheral blood and bone marrow was characterized by CD14, CD64, CD16 and CD56 expression. According to the histology of the bone marrow 2 cases were described as MDS, 1 as MDS/MPN, the rest as MPN with fibrosis in two of the cases. The cytogenetic risk was high in 5 patients and low in 10. According to CPSS one patient was with low risk, 3 with intermediate 1, 9 with intermediate 2 and 2 with high risk. Acute myeloid leukemia transformation occurred in 9 patients within median period of 13.1 months. The median survival after transformation was 2,5 months. The median survival in the whole group was 21.4 months. Conclusion: CMML is an aggressive disease. The prognosis of patients with CMML is poor, with low survival and high risk of transformation. The therapeutic options are limited

  • Open Access

    IMPACT OF THE IMPAIRED IRON HOMEOSTASIS ON THE PATHOGENESIS OF ANEMIA IN PRIMARY MYELOFIBROSIS

    by Liana Gercheva, Stela Dimitrova, Ilina Micheva, St. Marina, Bulgaria. Varna

    Anemia is a well established prognostic factor in primary myelofibrosis (PMF). Recent data suggests that markers of abnormal iron homeostasis, which are known to be affected by both iron overload and inflammation, may be involved in the pathogenesis of anemia in PMF.\ud Aim: To evaluate the relation between anemia, bone marrow fibrosis, prognostic score, survival and parameters of iron metabolism. \ud Materials and methods: We studied 72 patients with PMF. The following parameters were analyzed: degree of bone marrow fibrosis, hemoglobin level, MCV, components of iron homeostasis (total iron binding capacity (TIBC), ferritin, serum iron). The prognostic score was determined according to IPSS and DIPSS. Statistical analysis was performed by SPSS version 19.\ud Results: We found significant correlation between the level of hemoglobin and degree of bone marrow fibrosis and prognostic score. The MCV was analyzed in 56 of the patients and was found low in 9,5 % of them. However, there was no significant correlation between degree of fibrosis and the lower MCV. We found significant straight correlation between degree of fibrosis, serum ferritin level (p=0.006) and TIBC (p=0.018). In univariate analysis, significant feedback correlation was established between hemoglobin and serum ferritin level.\ud Conclusion: Our results reveal the possible role of the impaired iron metabolism in the pathogenesis of anemia in PMF. Further studies are needed in order to elucidate the precise mechanisms of this process

  • Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study)

    by Aleksander Skotnicki, Toshko J. Lissitchkov, Vasily Mamonov, Evgeny Buevich, Kazimierz Kuliczkowski, Stefcho Goranov, Janusz Kłoczko, Anna Klukowska, Svetlana Stankovic, Liana Gercheva, et al.


  • Open Access

    ERK, p38 AND NF-kappaB SIGNALING IN MONOCYTE DERIVED DENDRITIC CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME

    by Ilina Micheva, Liana Gercheva, Panos Ziros, Nicholas Zoumbos

    We have previously demonstrated that in patients with myelodysplastic syndrome (MDS) monocyte-derived DCs (MoDC) exhibit some phenotypic and functional abnormalities. However, the mechanisms underlying the defective response have not yet been clarified. \ud Aim: In the present study three different signaling pathways, ERK, p38K and NF-κB, were studied on MoDC from patients with MDS. \ud Materials and methods: 7 patients with MDS and 5 healthy controls were included in the study. MACS separated CD14 cells were cultured for DC generation and further stimulated with TNF-α and LPS. A migration assay and ELISA were performed for the analysis of migration and IL-12p70 secretion. Western blot analysis was used for the detection of the phosphorylated forms of ERK and p38K. NF-κB binding activity was evaluated by electrophoretic mobility shift assay (EMSA).\ud Results: In 6/7 patients the NF-κB binding activity in TNF-α and LPS stimulated MoDCs was lower compared to controls. This was accompanied by lower migratory capacity and IL-12p70 secretion. TNF-α and LPS induced phosphorylation of p38 and ERK at similar levels in control MoDC, whereas in MDS MoDC the pattern was heterogeneous with predominant activation of ERK over p38K. \ud Conclusion: Our results provide strong evidence that defective signaling through NF-κB and MAPK underlies the functional abnormalities of MoDC in patients with MDS